Jacques Dumas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacques Dumas has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Ajay Bhargava
3 shared publicationsAlka Shrikhande
3 shared publicationsGerald E Ranges
3 shared publicationsRobert Schoenleber
3 shared publicationsScott M Wilhelm
3 shared publicationsTimothy J Housley
3 shared publications
Latest Publications
- 1 September 2002
- Vol. 5 (5) , 718-27
Protein kinase inhibitors from the urea class.
Protein kinase inhibitors hold great potential as novel therapies for cancer and inflammatory disorders. While bis-aryl ureas have been reported as kinase inhibitors as early as 1996, a number of publications and patent applications appeared in the literature during the past two years. Three urea-based kinase inhibitors are currently undergoing clinical trials. The present review summarizes available data, and provides an overview of the structure-activity relationships against a variety of kinase targets, including p38, Raf-1 and cyclin-dependent kinases.
- 1 September 2002
- Vol. 5 (5) , 718-27
Protein kinase inhibitors from the urea class.
Protein kinase inhibitors hold great potential as novel therapies for cancer and inflammatory disorders. While bis-aryl ureas have been reported as kinase inhibitors as early as 1996, a number of publications and patent applications appeared in the literature during the past two years. Three urea-based kinase inhibitors are currently undergoing clinical trials. The present review summarizes available data, and provides an overview of the structure-activity relationships against a variety of kinase targets, including p38, Raf-1 and cyclin-dependent kinases.
- 1 June 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (12) , 1559-1562
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor
- 1 June 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (12) , 1559-1562
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor
- 1 July 2001
- Vol. 4 (4) , 378-89
Growth factor receptor kinase inhibitors: recent progress and clinical impact.
Inhibition of growth factor receptor kinases is one of the most promising therapeutic approaches for the treatment of cancer. This review focuses on the most recent progress in this area, and gives an overview of the compounds currently in the clinic, as well as key preclinical analogs.
- 1 July 2001
- Vol. 4 (4) , 378-89
Growth factor receptor kinase inhibitors: recent progress and clinical impact.
Inhibition of growth factor receptor kinases is one of the most promising therapeutic approaches for the treatment of cancer. This review focuses on the most recent progress in this area, and gives an overview of the compounds currently in the clinic, as well as key preclinical analogs.
- 1 March 2001
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 11 (3) , 405-429
Protein kinase inhibitors: emerging pharmacophores 1997 - 2000
Kinase inhibition is a major area for therapeutic intervention against a variety of diseases including cancer, inflammatory disorders and diabetes. While this mode of action remains very promising at this time, it faces critical challenges, such as drug safety, and biopharmaceutical profile. This review provides an update on kinase inhibitor pharmacophores from a structural standpoint. Advances in older inhibitor classes as well as new emerging lead structures will be presented.
- 1 March 2001
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 11 (3) , 405-429
Protein kinase inhibitors: emerging pharmacophores 1997 - 2000
Kinase inhibition is a major area for therapeutic intervention against a variety of diseases including cancer, inflammatory disorders and diabetes. While this mode of action remains very promising at this time, it faces critical challenges, such as drug safety, and biopharmaceutical profile. This review provides an update on kinase inhibitor pharmacophores from a structural standpoint. Advances in older inhibitor classes as well as new emerging lead structures will be presented.
- 1 September 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (18) , 2047-2050
Discovery of a new class of p38 kinase inhibitors
- 1 September 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (18) , 2047-2050
Discovery of a new class of p38 kinase inhibitors
- 1 September 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (18) , 2051-2054
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors
- 1 September 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (18) , 2051-2054
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors